ArticleMolecular biotechnology2022
Biodegradable Zn-2Ag-0.04Mg Alloy for Bone Regeneration In Vivo.
Article in Molecular biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effect of Combined Equal-Channel Angular Pressing and Rolling on the Microstructure and Mechanical Properties of Zn-0.5Ag-0.2Mg Alloy.Materials (Basel, Switzerland) · 2025Article
- Zinc based biodegradable metals for bone repair and regeneration: Bioactivity and molecular mechanisms.Materials today. Bio · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To evaluate the bone regeneration capacity of Zn-2Ag-0.04Mg alloy scaffold in vivo. Zn, Zn-2Ag and Zn-2Ag-0.04Mg scaffolds were implanted in the femur of New Zealand rabbits, and the degradation of the scaffolds and the regeneration of the bone were observed at 6th week and 6th month. Two-dimensional and three-dimensional micro-CT results showed the new bone in Zn-2Ag-0.04Mg alloy scaffold group was significant more than Zn scaffold group, the bone volume in Zn-2Ag-0.04Mg was higher. Moreover, the osteogenic index in the Zn-2Ag-0.04Mg alloy scaffold group was also higher than Zn scaffold group. At 6th month, the scaffold of Zn-2Ag-0.04Mg was smaller than Zn group or Zn-2Ag group. HE staining of the liver, kidney, and heart did not detect any abnormalities, confirmed the biosafety of the Zn-2Ag-0.04Mg alloy scaffold. The Zn-Ag-0.04Mg alloy scaffold exhibits good biocompatibility and bone regeneration ability in vivo.
Indexed as
Identifiers
35260964What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.